Nationwide Study of Factors Impacting Survival Outcome and Consequences in Children with Reactivation/Refractory Langerhans Cell Histiocytosis
Issued Date
2024-05-01
Resource Type
eISSN
2476762X
Scopus ID
2-s2.0-85194859561
Pubmed ID
38809656
Journal Title
Asian Pacific journal of cancer prevention : APJCP
Volume
25
Issue
5
Start Page
1831
End Page
1839
Rights Holder(s)
SCOPUS
Bibliographic Citation
Asian Pacific journal of cancer prevention : APJCP Vol.25 No.5 (2024) , 1831-1839
Suggested Citation
Monsereenusorn C., Suwannaying K., Buaboonnam J., Sathitsamitphong L., Techavichit P., Pakakasama S., Chainansamit S.o., Anurathapan U., Komvilaisak P., Traivaree C., Sanpakit K., Charoenkwan P., Seksarn P. Nationwide Study of Factors Impacting Survival Outcome and Consequences in Children with Reactivation/Refractory Langerhans Cell Histiocytosis. Asian Pacific journal of cancer prevention : APJCP Vol.25 No.5 (2024) , 1831-1839. 1839. doi:10.31557/APJCP.2024.25.5.1831 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/98681
Title
Nationwide Study of Factors Impacting Survival Outcome and Consequences in Children with Reactivation/Refractory Langerhans Cell Histiocytosis
Corresponding Author(s)
Other Contributor(s)
Abstract
BACKGROUND: Disease reactivation/refractory remains a major challenge in managing Langerhans cell histiocytosis (LCH). Outcomes and late sequelae should be explored. METHODS: A multi-institutional retrospective study was conducted to describe clinical characteristics, predictive factors, outcomes and late sequelae of pediatric reactivation/refractory LCH in Thailand. RESULTS: In all, 47 patients were studied, 25 (53.2%) patients had disease reactivation and 22 (46.8%) patients had refractory LCH. The median reactivation and refractory time were 1.59 and 0.33 years from diagnosis, respectively (p <0.001). The most common site of reactivation/refractory was the bone (n = 26, 55%), and 20 (42.6%) patients developed late sequelae. The 5-year overall survival (OS) was 76.1%. Patients with reactivation and refractory LCH performed similarly in 5-year OS (88% vs. 63%, p = 0.055). Prognostic factors associated with mortality were liver, spleen, hematopoietic system and lung reactivation (p <0.05). Lung reactivation was the only independent risk factor associated with the survival outcome (p = 0.002). CONCLUSIONS: The outcomes of pediatric patients between reactivation and refractory LCH in Thailand were similarly desirable and mortality was minimal although late sequelae may evolve. Pulmonary reactivation/refractory was an independent risk factor associated with survival.